The size of the Middle East & Africa Non-Invasive Prenatal Testing Market was valued at USD 0.13 Billion in 2022. It is further projected to be growing at a CAGR of 4.93%, to touch USD 0.16 billion by 2027.
The presence of multiple large-scale enterprises, for instance, will have a beneficial impact on the market's growth in this region during the forecast period. In addition, the increased prevalence of genetic abnormalities, rapid adoption of next-generation sequencing, new product introductions, an increased number of non-invasive prenatal testing service providers are further promoting the NIPT market in the Middle East and Africa. Furthermore, the rising number of stillbirths in the Middle East and Africa is likely to provide a significant growing opportunity for early illness detection, which is expected to favor the market in the coming future.
Furthermore, the advantages of non-invasive prenatal testing over conventional prenatal tests, such as their non-invasive nature, higher accuracy, and shorter procedure time, are expected to accelerate the growth of the NIPT market in the Middle East and Africa during the forecast period. In addition, the expansion of the market in this region is expected to be fueled by innovations in existing tests in terms of advanced functionality, improved chemistry, and bioinformatics analysis. Furthermore, one of the market's main driving forces is the improvement of payment policies for ordinary and low-risk pregnancies.
However, a lack of test accessibility in emerging nations, ethical issues, and rigorous government regulations are only a few factors that limit the Middle East and Africa NIPT market growth.
This research report on the Middle East and Africa non-invasive prenatal testing market has been segmented and sub-segmented into the following categories.
By End User:
In terms of revenue share, the Middle East and Africa had a middle part of the global market in 2020. The Middle East and Africa Non-Invasive Prenatal Testing market are expected to rise healthily during the forecast period. The presence of important companies, a large number of research activities, and a highly structured healthcare market drive the market in the region.
Increased investment by key players in the Middle East and Africa and rising maternal age are expected to drive the market for non-invasive prenatal testing in the Middle East and Africa. As a result, the country is expected to be the most attractive market for non-invasive prenatal testing, with a high attractiveness index, due to the early adoption of technology.
Furthermore, the rising acceptance rate for prenatal testing and increased health consciousness and understanding among the general public about the benefits and significance of such testing are influencing the regional market growth.
Other genetic diseases, such as spina bifida, cleft palate, and sickle cell anemia, are being diagnosed and treated in the early stages of embryonic development in countries like the UAE and Kuwait by healthcare providers and expecting parents. Furthermore, the changing trend toward childbearing at a young age for the mother has a beneficial impact on regional market growth.
Increasing maternal age can contribute to various health issues, including high blood pressure, decreased fertility, an increased risk of miscarriage, and an increased risk of genetic abnormalities in the fetus.
KEY MARKET PLAYERS:
Companies playing an active role in the MEA non-invasive prenatal testing market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.6 Y-o-Y Growth Analysis, By Instruments
5.1.7 Market Attractiveness Analysis, By Instruments
5.1.8 Market Share Analysis, By Instruments
5.2.3 Cell-Free DNA (cf-DNA)
5.2.4 Y-o-Y Growth Analysis, By Method
5.2.5 Market Attractiveness Analysis, By Method
5.2.6 Market Share Analysis, By Method
5.3.5 Rh factor
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.3 Diagnostic Labs
5.4.4 Y-o-Y Growth Analysis, By End User
5.4.5 Market Attractiveness Analysis, By End User
5.4.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Instruments
220.127.116.11 By Method
18.104.22.168 By Application
22.214.171.124 By End User
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Instruments
184.108.40.206 By Method
220.127.116.11 By Application
18.104.22.168 By End User
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Instruments
188.8.131.52 By Method
184.108.40.206 By Application
220.127.116.11 By End User
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Koninklijke Philips N.V
8.3 Thermo Fisher Scientific
8.4 Hoffman-La Roche
8.5 Pacific Biosciences of California
8.7 QIAGEN N.V
8.8 Agilent Technologies
8.9 Beijing Genomics Institute
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.